Delirium and Distressing Movements: Palliative Sedation Therapy in Patients with Refractory Terminal Delirium when Standard Treatment Options are Limited

2019 ◽  
Author(s):  
Dan Partain
Keyword(s):  
Standard Treatment ◽  
Treatment Options ◽  
Palliative Sedation ◽  
Palliative Sedation Therapy

scholarly journals PERIOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER

2013 ◽  
Vol 50 (3) ◽  
pp. 236-242 ◽  
Author(s):  
Thales Paulo BATISTA ◽  
Candice Amorim de Araujo Lima SANTOS ◽  
Gustavo Fernandes Godoy ALMEIDA
Keyword(s):  
Gastric Cancer ◽  
Therapeutic Strategy ◽  
Multimodal Therapy ◽  
Standard Treatment ◽  
Treatment Options ◽  
Locally Advanced ◽  
Special Focus ◽  
Perioperative Chemotherapy ◽  
Locally Advanced Gastric Cancer ◽  
Advanced Stages

Gastric cancer is one of the most common cancers and a main cause of cancer-related death worldwide, since the majority of patients suffering of this malignancy are usually faced with a poor prognosis due to diagnosis at later stages. In order to improve treatment outcomes, the association of surgery with chemo and/or radiotherapy (multimodal therapy) has become the standard treatment for locally advanced stages. However, despite several treatment options currently available for management of these tumors, perioperative chemotherapy has been mainly accepted for the comprehensive therapeutic strategy including an appropriated D2-gastrectomy. This manuscript presents a (nonsystematic) critical review about the use of perioperative chemotherapy, with a special focus on the drugs delivery.

scholarly journals Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review

2020 ◽  
Vol 4 (5) ◽  
pp. 815-818 ◽  
Author(s):  
Yazan Migdady ◽  
Asiri Ediriwickrema ◽  
Ryan Patrick Jackson ◽  
Wendy Kadi ◽  
Ridhi Gupta ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Successful Treatment ◽  
Standard Treatment ◽  
Treatment Options ◽  
Allogeneic Transplant ◽  
Novel Treatment ◽  
Short Course ◽  
Key Points ◽  
Lymphocyte Populations

Key Points A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations. A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.

scholarly journals Hereditary Hemorrhagic Telangiectasia: Systemic Therapies, Guidelines, and an Evolving Standard of Care

Blood ◽  
2020 ◽  
Author(s):  
Hanny Al-Samkari
Keyword(s):  
Hereditary Hemorrhagic Telangiectasia ◽  
Standard Treatment ◽  
Treatment Options ◽  
Standard Of Care ◽  
Diagnosis And Treatment ◽  
International Guidelines ◽  
Clinical Recommendations ◽  
Antiangiogenic Therapies ◽  
Systemic Therapies ◽  
Second International

Hereditary hemorrhagic telangiectasia (HHT) management is evolving due to the emergence and development of antiangiogenic therapies to eliminate bleeding telangiectasias and achieve hemostasis. This is reflected in recent clinical recommendations published in the Second International Guidelines for the Diagnosis and Treatment of HHT, in which systemic therapies including antiangiogenics and antifibrinolytics are now recommended as standard treatment options for bleeding. This review highlights the new recommendations especially relevant to hematologists in managing bleeding, anticoagulation, and anemia in patients with HHT.

scholarly journals P181 Exploring the Experiences and Perceptions of Nurses in the Provision of Palliative Sedation Therapy

2016 ◽  
Vol 52 (6) ◽  
pp. e115
Author(s):  
Charlotte Robinson ◽  
Rosalie Starzomski ◽  
Karen MacKinnon
Keyword(s):  
Palliative Sedation ◽  
Palliative Sedation Therapy

scholarly journals Active surveillance for prostate cancer: to whom, when and how

2019 ◽  
Vol 10 (3) ◽  
pp. 37-44
Author(s):  
M. S. Taratkin ◽  
E. A. Laukhtina ◽  
K. I. Adelman ◽  
Y. G. Alyaev ◽  
L. M. Rapoport ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Active Surveillance ◽  
Standard Treatment ◽  
Treatment Options ◽  
Low Risk ◽  
External Beam Radiation ◽  
Treatment Modalities ◽  
Malignant Neoplasms ◽  
Cancer Specific Survival ◽  
Beam Radiation

Prostate cancer (PCa) is the most common oncological disease among men. It is important to note that over 50% of the first identified primary malignant neoplasms of prostate are low - risk PCa. Recently, radical prostatectomy and external beam radiation therapy have been the standard treatment options for PCa. According to recent data, patients with low - risk PCa have a favourable prognosis because of the slow progression of the disease. Some studies show no links between 10-year cancer - specific survival and treatment modalities and no progression even in the absence of therapy. Active surveillance (AS) allows avoiding unnecessary treatment in men who do not require immediate intervention but achieves the correct timing for curative treatment in those who eventually need it. According to the guidelines of the European Association of Urology, AS is one of the standard treatment options for low - risk PCa and should be consideredfor all patients in this category. The advantage of AS is to improve the quality of life in men with low - risk PCa and to delay surgical interventions as much as possible. However, despite widespread AS worldwide, there are only a few centres, which use it routinely in Russia. In this review, we would like to shed some light on the most important questions of AS strategy: what criteria should we use for selection of patients for AS strategy? How often should patient visit the urologist, control PSA level, and undergo prostate biopsy? When should a doctor change strategy and turn to active treatment? In this article, we considered indications for AS in men with PCa and showed the most recent data on the efficacy and relevance of this modality.

scholarly journals PEG-Asparaginase Single-Agent Rescue in an Advanced Case of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma.

2021 ◽  
Author(s):  
Emiliano Barbieri ◽  
Stefano Pozzi ◽  
Roberta Gelmini ◽  
Luca Roncati ◽  
Monica Maccaferri ◽  
...  
Keyword(s):  
T Cell ◽  
Standard Treatment ◽  
Cell Lymphoma ◽  
Treatment Options ◽  
Single Agent ◽  
T Cell Lymphoma ◽  
Related Complication ◽  
Peripheral T Cell Lymphoma ◽  
Future Studies ◽  
The Subject

Abstract MEITL is a very rare and highly aggressive peripheral T-cell lymphoma with poor prognosis and for which there is no standard treatment. Patients with relapsed/refractory disease have few treatment options and many still die of disease progression. Here we report the case of a 65-year-old woman affected by MEITL, progressing after initial treatment with an anthracycline-based chemotherapy and surgery, who received single-agent PEG-asparaginase salvage therapy at our institution. The treatment proved to be rapidly effective in controlling the disease and its associated paraneoplastic features. Nevertheless, toxicity was high and the patient died due to a treatment-related complication. The case we described brings new evidences on the effectiveness of PEG-asparaginase therapy in MEITL patients. Whether PEG-asparaginase should be included in the treatment course of MEITL patients could be the subject of future studies.

scholarly journals The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma

2019 ◽  
Vol 12 ◽  
pp. 175628481986976 ◽  
Author(s):  
Gagandeep Brar ◽  
Manish A. Shah
Keyword(s):  
Gastric Cancer ◽  
Immune Checkpoint Inhibitors ◽  
Standard Treatment ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Gastroesophageal Junction ◽  
Response To Treatment ◽  
Gastroesophageal Junction Adenocarcinoma ◽  
Tumor Types

Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have become standard treatment options in numerous tumor types. In this review, we discuss the current and evolving use of checkpoint blockade, focusing on the anti-PD-1 inhibitor, pembrolizumab, for use in advanced gastric and gastroesophageal cancers.

scholarly journals Recurrent lacrimal abscess in infant

2014 ◽  
Vol 6 (2) ◽  
pp. 121-123
Author(s):  
Monojit Mondal ◽  
Biswajit Biswas ◽  
Sumanta Laha ◽  
Atanu Roy ◽  
Kanai Lal Barik ◽  
...  
Keyword(s):  
Standard Treatment ◽  
Treatment Options ◽  
Treatment Protocol ◽  
Nasolacrimal Duct ◽  
Lacrimal Sac ◽  
Medical Sciences ◽  
Incision And Drainage ◽  
One Year ◽  
Antibiotic Cover ◽  
Main Complication

Acute dacryocystitis at or shortly after birth is uncommon and its main complication, formation of lacrimal sac abscess, is rare. Uniform and standard treatment protocol for this condition has not been established till date. We report on a 2 month old infant with an abscess of the lacrimal sac. He was treated for similar condition on day 6 of his life by incision and drainage; unfortunately, the condition recurs. This time, he was managed with incision and drainage under systemic antibiotic cover; and an early probing of the nasolacrimal duct (NLD) was done on 7th post-operative day. The patient was followed up for a period of one year without any further recurrence and complication. Pathophysiology of the condition and possible treatment options in children have been discussed.DOI: http://dx.doi.org/10.3126/ajms.v6i2.10458Asian Journal of Medical Sciences Vol.6(2) 2015 121-123

Sign in / Sign up

Export Citation Format

Share Document